Access Vascular Logo Hi Res.png
New Access Vascular Clinical Studies Find Catheters Composed of Advanced Biomaterials Significantly Reduce Complication Rates
September 20, 2021 08:00 ET | Access Vascular
BEDFORD, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Access Vascular, Inc. (AVI), a company addressing the most common and costly vascular access complications through its advanced biomaterial...
RapidPulse Launches With $15 Million Series A Financing for Ischemic Stroke Therapy
June 23, 2021 09:00 ET | RapidPulse, Inc
MIAMI, June 23, 2021 (GLOBE NEWSWIRE) -- RapidPulse, Inc., a privately-held medical device company developing a novel aspiration system to treat ischemic stroke, today announced the closing of a $15...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
Study Identifies New Role of BioAegis’ ‘Inflammation Regulator’ Gelsolin Relevant for a Range of Inflammatory Diseases
April 08, 2021 18:58 ET | BioAegis Therapeutics
Gelsolin mitigates vascular damage by preventing release of IL-1β microparticles after trauma of high pressure and decompression.  Gelsolin is non-immunosuppressive unlike current treatments to quell...
Velano’s PIVO™ Named 2018 MedTech Breakthrough Awards’ Best Overall Medical Device Solution
June 06, 2018 13:06 ET | Velano Vascular
SAN FRANCISCO, June 06, 2018 (GLOBE NEWSWIRE) -- Vascular access technology innovator Velano Vascular’s PIVO™ needle-free device for blood draws was named Best Overall Medical Device Solution by the...
58437_VVlogopngcopy.jpg
Velano Vascular Named 2018’s Gold Edison Award™ Winner
April 17, 2018 08:00 ET | Velano Vascular
SAN FRANCISCO, April 17, 2018 (GLOBE NEWSWIRE) -- Vascular access technology innovator Velano Vascular today announced that its PIVO™ needle-free device for blood draws was named the 2018 Gold...
58437_VVlogopngcopy.jpg
Velano Vascular to Address Healthcare Innovation at Upcoming Spring Conferences
April 10, 2018 08:00 ET | Velano Vascular
SAN FRANCISCO, April 10, 2018 (GLOBE NEWSWIRE) -- Vascular access technology innovator Velano Vascular today announced that company leadership will present at a number of premier healthcare...
New Proteon Logo - full color RGB.jpg
Proteon Therapeutics Announces Overview of Phase 1 Clinical Program of Investigational Vonapanitase in Peripheral Artery Disease to be Presented at the 28th Transcatheter Cardiovascular Therapeutics (TCT) Conference
October 25, 2016 08:00 ET | Proteon Therapeutics, Inc.
WALTHAM, Mass., Oct. 25, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
New Proteon Logo - full color RGB.jpg
Proteon Therapeutics Announces Publication in the Journal of Cardiovascular Pharmacology of Promising Nonclinical Results for Vonapanitase in Peripheral Artery Disease
April 13, 2016 08:00 ET | Proteon Therapeutics, Inc.
WALTHAM, Mass., April 13, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
New Proteon Logo - full color RGB.jpg
Journal of Cardiovascular Pharmacology Publishes Positive Nonclinical Results of Proteon Therapeutics' PRT-201 in Peripheral Artery Disease
January 08, 2015 16:30 ET | Proteon Therapeutics, Inc.
WALTHAM, Mass., Jan. 8, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
New Proteon Logo - full color RGB.jpg
Proteon Therapeutics Announces Pricing of Initial Public Offering
October 21, 2014 19:36 ET | Proteon Therapeutics, Inc.
WALTHAM, Mass., Oct. 21, 2014 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc., a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and...